ME02275B - Polimorfni oblik rotigotina - Google Patents
Polimorfni oblik rotigotinaInfo
- Publication number
- ME02275B ME02275B MEP-2015-136A MEP13615A ME02275B ME 02275 B ME02275 B ME 02275B ME P13615 A MEP13615 A ME P13615A ME 02275 B ME02275 B ME 02275B
- Authority
- ME
- Montenegro
- Prior art keywords
- rotigotine
- polymorphic form
- medicinal substance
- parkinson
- pharmaceutical composition
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims 20
- 229960003179 rotigotine Drugs 0.000 title claims 20
- 239000012907 medicinal substance Substances 0.000 claims 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960003638 dopamine Drugs 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Polimorfni oblik (II) Rotigotina ((-)-5,6,7,8-tetrahidro-6-[propil[2-(2-tienil) etil]-amino]-1-naftalenol) koji ima najmanje jedno od:Rendgenski spektar praha koji sadrži pikove pri sledećim ° 2θ uglovima (± 0.2): 12.04, 13.68, 17.72 i 19.01, mereno sa Cu-Kα zračenjem (1.54060 Å);Raman spektar koji sadrži pikove pri sledećim talasnim brojevima (± 3 cm-1) odabranim od: 226.2, 297.0, 363.9, 710.0, 737.3, 743.3, 750.8, 847.3, 878.3, 1018.7, 1075.6, 1086.2, 1214.3, 1255.1, 1278.2, 1330.7, 1354.3 i 1448.7;DSC pik sa Tonset na 97°C ± 2°C mereno pri brzini zagrevanja od 10 °/min;tačku topljenja na 97°C ± 2°C.
2. Polimorfni oblik Rotigotina koji ima rendgenski spektar difrakcije praha meren sa Cu-Kα zračenjem (1.54060 Å) suštinski kao onaj prikazan na Slici 1.
3. Rotigotin lekovita supstanca koja sadrži najmanje 5% polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2.
4. Rotigotin lekovita supstanca koja sadrži najmanje 50% polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2.
5. Rotigotin lekovita supstanca koja sadrži najmanje 90% polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2.
6. Rotigotin lekovita supstanca koja sadrži najmanje 95% polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2.
7. Rotigotin lekovita supstanca prema bilo kojem od patentnih zahteva 3-6 za upotrebu kao terapeutski aktivna supstanca.
8. Kristalni polimorf prema bilo kojem od patentnih zahteva 1 do 2 za primenu kao terapeutski aktivna supstanca.
9. Upotreba polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2 ili Rotigotin lekovite supstance prema patentnim zahtevima 3-6 i najmanje jednog farmaceutski prihvatljivog ekscipijensa u postupku za proizvodnju farmaceutske kompozicije.
10. Upotreba prema patentnom zahtevu 9, naznačena time što je farmaceutska kompozicija u obliku transdermalnog terapeutskog sistema.
11. Metod za dobijanje farmaceutske kompozicije korišćenjem polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2 ili Rotigotin lekovite supstance prema zahtevima 3-6 i najmanje jednog farmaceutski prihvatljivog ekscipijensa.
12. Metod prema zahtevu 11, u kojem je farmaceutska kompozicija u obliku transdermalnog terapeutskog sistema.
13. Polimorfni oblik Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2 ili Rotigotin lekovita supstanca prema zahtevima 3-6 za upotrebu u postupku lečenja pacijenta koji pati od poremećaja povezanih sa dopaminom gde je pomenuti poremećaj odabran od Parkinsonove Bolesti Parkinsonovog plus sindroma, depresije, fibromijalgije i/ili sindroma nemirnih nogu.
14. Upotreba polimorfnog oblika Rotigotina kako je definisano u bilo kojem od patentnih zahteva 1-2 ili Rotigotin lekovite supstance prema patentnim zahtevima 3-6 za proizvodnju leka za lečenje pacijenta koji pati od poremećaja povezanih sa dopaminom gde je sa dopaminom povezani poremećaj odabran od Parkinsonove bolesti, Parkinsonovog plus sindroma, depresije, fibromijalgije i/ili sindroma nemirnih nogu.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99072107P | 2007-11-28 | 2007-11-28 | |
| EP07121795 | 2007-11-28 | ||
| EP08166576 | 2008-10-14 | ||
| PCT/EP2008/066137 WO2009068520A2 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
| EP08853236.1A EP2215072B1 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02275B true ME02275B (me) | 2016-02-20 |
Family
ID=40676399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-136A ME02275B (me) | 2007-11-28 | 2008-11-25 | Polimorfni oblik rotigotina |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8592477B2 (me) |
| EP (1) | EP2215072B1 (me) |
| JP (1) | JP5391204B2 (me) |
| KR (1) | KR101694551B1 (me) |
| CN (1) | CN101970422B (me) |
| AR (1) | AR070036A1 (me) |
| AU (1) | AU2008328920B2 (me) |
| CA (1) | CA2703561C (me) |
| DK (1) | DK2215072T3 (me) |
| EA (1) | EA017836B1 (me) |
| ES (1) | ES2547231T3 (me) |
| HR (1) | HRP20150956T1 (me) |
| HU (1) | HUE027647T2 (me) |
| IL (1) | IL204991A (me) |
| ME (1) | ME02275B (me) |
| MX (1) | MX2010005925A (me) |
| MY (1) | MY165575A (me) |
| NZ (1) | NZ584363A (me) |
| PH (1) | PH12013501503A1 (me) |
| PL (1) | PL2215072T3 (me) |
| PT (1) | PT2215072E (me) |
| RS (1) | RS54235B1 (me) |
| SG (1) | SG10201610626PA (me) |
| SI (1) | SI2215072T1 (me) |
| TW (1) | TWI418349B (me) |
| WO (1) | WO2009068520A2 (me) |
| ZA (1) | ZA201002192B (me) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| NZ551356A (en) | 2004-05-11 | 2009-09-25 | Emotional Brain Bv | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| WO2008146284A2 (en) | 2007-05-30 | 2008-12-04 | Chemagis Ltd. | Crystalline rotigotine base and preparation process therefor |
| EA017836B1 (ru) | 2007-11-28 | 2013-03-29 | ЮСиБи ФАРМА ГМБХ | Новая полиморфная форма ротиготина и способ ее получения |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
| CN104189912A (zh) | 2009-12-22 | 2014-12-10 | 优时比制药有限公司 | 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮 |
| WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
| WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
| DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
| TW201431570A (zh) * | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| WO2014136122A1 (en) * | 2013-03-04 | 2014-09-12 | Mylan Laboratories Limited | Process for the preparation of rotigotine polymorphic form-i |
| US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
| US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| WO2015177212A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| WO2015177209A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| WO2015186138A1 (en) * | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| ES2988819T3 (es) | 2017-12-19 | 2024-11-21 | Hisamitsu Pharmaceutical Co | Parche que contiene rotigotina |
| KR102721898B1 (ko) | 2019-02-15 | 2024-10-24 | 히사미쓰 세이야꾸 가부시키가이샤 | 로티고틴 안정화 방법 |
| EP3854388B1 (de) | 2020-01-24 | 2023-10-04 | Luye Pharma Switzerland AG | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber |
| WO2023157865A1 (ja) | 2022-02-21 | 2023-08-24 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
| JP7322324B1 (ja) | 2022-02-21 | 2023-08-07 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
| EP4628076A1 (en) | 2022-12-01 | 2025-10-08 | Hisamitsu Pharmaceutical Co., Inc. | Rotigotine-containing patch and method for improving stability of rotigotine |
| WO2024260959A1 (en) | 2023-06-19 | 2024-12-26 | Inke, S.A. | Process for preparing optically active secondary amines and their use as intermediates |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4320148A (en) * | 1980-11-24 | 1982-03-16 | Smithkline Corporation | 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity |
| US5177112A (en) * | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US4540691A (en) | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
| US4885308A (en) | 1984-08-13 | 1989-12-05 | Nelson Research & Development Co. | Method and compositions for treatment of parkinsonism syndrome in mammals |
| US5214156A (en) | 1988-03-25 | 1993-05-25 | The Upjohn Company | Therapeutically useful tetralin derivatives |
| DE69032725T2 (de) * | 1989-05-31 | 1999-04-08 | Pharmacia & Upjohn Co., Kalamazoo, Mich. | ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate |
| US5545755A (en) | 1989-05-31 | 1996-08-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
| US5486611A (en) | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
| US5151446A (en) | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| SE9301732D0 (sv) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins |
| US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| DE19814083C2 (de) | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| AR026505A1 (es) * | 1999-11-23 | 2003-02-12 | Aderis Pharmaceuticals Inc | Proceso mejorado para la preparacion de aminotetralinas sustituidas con nitrogeno |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| DK1256340T3 (da) | 2001-05-08 | 2003-12-01 | Sanol Arznei Schwarz Gmbh | Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom |
| FR2828212B1 (fr) | 2001-08-03 | 2003-10-31 | Aventis Pharma Sa | Methodes de diagnostic et de pronostic de la maladie de parkinson |
| FR2829028B1 (fr) * | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| MXPA04009352A (es) * | 2002-04-18 | 2005-01-25 | Pharmacia Corp | Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2). |
| US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| US20060216336A1 (en) * | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| WO2004039320A2 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF |
| EP1426049B1 (en) * | 2002-12-02 | 2005-05-18 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| US7348762B2 (en) | 2003-05-01 | 2008-03-25 | Sony Corporation | Battery pack and method for producing battery pack |
| DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| WO2008146284A2 (en) | 2007-05-30 | 2008-12-04 | Chemagis Ltd. | Crystalline rotigotine base and preparation process therefor |
| WO2009063170A1 (en) | 2007-11-16 | 2009-05-22 | Pliva Hrvatska D.O.O. | Preparation of crystalline rotigotine base |
| EA017836B1 (ru) | 2007-11-28 | 2013-03-29 | ЮСиБи ФАРМА ГМБХ | Новая полиморфная форма ротиготина и способ ее получения |
| EP2281559A1 (en) * | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| CN104189912A (zh) * | 2009-12-22 | 2014-12-10 | 优时比制药有限公司 | 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮 |
| WO2015186138A1 (en) | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
-
2008
- 2008-11-25 EA EA201000384A patent/EA017836B1/ru not_active IP Right Cessation
- 2008-11-25 RS RS20150578A patent/RS54235B1/sr unknown
- 2008-11-25 PT PT88532361T patent/PT2215072E/pt unknown
- 2008-11-25 HU HUE08853236A patent/HUE027647T2/en unknown
- 2008-11-25 PL PL08853236T patent/PL2215072T3/pl unknown
- 2008-11-25 SG SG10201610626PA patent/SG10201610626PA/en unknown
- 2008-11-25 EP EP08853236.1A patent/EP2215072B1/en not_active Revoked
- 2008-11-25 ME MEP-2015-136A patent/ME02275B/me unknown
- 2008-11-25 AU AU2008328920A patent/AU2008328920B2/en active Active
- 2008-11-25 NZ NZ584363A patent/NZ584363A/xx not_active IP Right Cessation
- 2008-11-25 ES ES08853236.1T patent/ES2547231T3/es active Active
- 2008-11-25 US US12/744,989 patent/US8592477B2/en active Active
- 2008-11-25 SI SI200831499T patent/SI2215072T1/sl unknown
- 2008-11-25 MX MX2010005925A patent/MX2010005925A/es active IP Right Grant
- 2008-11-25 DK DK08853236.1T patent/DK2215072T3/en active
- 2008-11-25 CA CA2703561A patent/CA2703561C/en active Active
- 2008-11-25 MY MYPI2010001680A patent/MY165575A/en unknown
- 2008-11-25 HR HRP20150956TT patent/HRP20150956T1/hr unknown
- 2008-11-25 JP JP2010535352A patent/JP5391204B2/ja active Active
- 2008-11-25 CN CN200880110877.9A patent/CN101970422B/zh not_active Ceased
- 2008-11-25 WO PCT/EP2008/066137 patent/WO2009068520A2/en not_active Ceased
- 2008-11-25 KR KR1020107010562A patent/KR101694551B1/ko active Active
- 2008-11-26 US US12/324,166 patent/US8232414B2/en active Active
- 2008-11-26 TW TW097145595A patent/TWI418349B/zh active
- 2008-11-28 AR ARP080105189A patent/AR070036A1/es unknown
-
2010
- 2010-03-29 ZA ZA2010/02192A patent/ZA201002192B/en unknown
- 2010-04-11 IL IL204991A patent/IL204991A/en active IP Right Grant
-
2013
- 2013-07-15 PH PH12013501503A patent/PH12013501503A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02275B (me) | Polimorfni oblik rotigotina | |
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
| JP2011516417A5 (me) | ||
| FI3746126T3 (fi) | Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi | |
| HRP20210086T1 (hr) | Kristalni metiltioninij-klorid-hidrati | |
| JP2007500154A5 (me) | ||
| HRP20161121T1 (hr) | Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost | |
| JP2009537498A5 (me) | ||
| JP2011527333A5 (me) | ||
| RU2014121065A (ru) | Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение | |
| JP2013509411A5 (me) | ||
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| MX2011007779A (es) | Formulaciones galenicas de compuestos organicos. | |
| JP2006249089A5 (me) | ||
| JP2013541583A5 (me) | ||
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| JP2013536837A5 (me) | ||
| JP2012508256A5 (me) | ||
| JP2012510985A5 (me) | ||
| JP2010500284A5 (me) | ||
| JP2010529130A5 (me) | ||
| ATE506941T1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon | |
| CA2561452A1 (en) | Neuroprotective benzoate and benzamide compounds | |
| JP2012511571A5 (me) |